Autologous CD34+ hematopoietic stem cells augmented with allogeneic mitochondria (MAT)

Autologous CD34+ hematopoietic stem cells augmented with allogeneic mitochondria represents a novel cell-based therapeutic modality known as Mitochondrial Augmentation Therapy (MAT). This approach is specifically designed to treat primary mitochondrial diseases, such as Pearson Syndrome, which are caused by large-scale deletions in mitochondrial DNA (mtDNA) that lead to severe energy failure and bone marrow dysfunction (Jacoby et al., 2022, Nature Communications). The process involves harvesting a patient's own CD34+ hematopoietic stem cells and enriching them ex vivo with healthy, functional mitochondria isolated from a donor, typically a healthy family member (Minovia Therapeutics, 2024). Once these augmented cells are re-infused, they are intended to engraft in the bone marrow and produce functional blood cells with restored metabolic capacity. By increasing the levels of wild-type mtDNA within the progenitor population, the therapy aims to improve cellular ATP production and alleviate the clinical manifestations of mitochondrial deficiency (ClinicalTrials.gov NCT03384420). This modality is distinct from traditional gene therapy as it does not involve direct modification of the nuclear genome but rather the physical transfer of organelles to rescue cellular function.

Other names

Mitochondrial Augmentation TherapyMNV-BM-BLDMitochondrial-enriched CD34+ cellsAutologous CD34+ cells with donor mitochondria

Restoration of mitochondrial function in hematopoietic stem cells through the ex vivo uptake of healthy allogeneic mitochondria, which increases ATP production and shifts the ratio of wild-type to mutant mitochondrial DNA (heteroplasmy) in favor of functional metabolism.